Effects of Passive Immunization on Immunogenicity of Filovirus Vaccines
Abstract
The overall research idea of this proposal is to ascertain the feasibility of providing short-term protection against Ebola virus infection while co-administering Ebola virus vaccines to provide long-term protection against disease. Ebola virus vaccine candidates (a live replicating vesicular stomatitis virus (VSV) expressing Ebola-GP and a replication-deficient adenovirus (AdV) expressing Ebola GP) have been used in humans. For therapeutic purposes, monoclonal antibodies (ZMapp, mAb114) and antiviral small molecules (Remdesivir) are also being tested in human infections. However, neither antibody therapy nor small molecule inhibitors of Ebola virus replication will protect against infection long-term, and vaccines do not provide immediate protection. To that end, this proposal will test multiple strategies to combine therapeutic drugs with vaccines to generate rapid short-term as well as long-term protection against Ebola virus. In the first and second year we found that administration of neutralizing antibodies had an effect on the short-term immunogenicity of both VSV and AdV vaccines and that VSV elicited substantially higher IgG titers than AdV vaccine. In year three, we found there was no significant impact on antibodies elicited by VSV vaccine after treatment with the antiviral small molecule remdesivir. Ongoing studies in the no-cost-extension phase of the work will assess impact of co-administration of vaccines with antibodies or antivirals on animal survival in live-virus challenge models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1190762
Entities
People
- Chunyan Ye
- Elizabeth C. Clarke
- Robert Nofchissey
- Steven B. Bradfute
Organizations
- University of New Mexico